Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00657345 · ClinicalTrials.gov registry record
IRS Proteins and Trastuzumab Resistance
A clinical trial, sponsored by University of Massachusetts, Worcester.
- Completed
- Registry status
- 9
- Enrollment target
NCT00657345 is a clinical trial that has completed, run by University of Massachusetts, Worcester. The registered enrollment target is 9 participants.
The verdict
NCT00657345 has completed, sponsored by University of Massachusetts, Worcester.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
Significant progress has been made in the treatment of women with Her2 positive breast cancer who are treated with trastuzumab, a humanized monoclonal antibody that inhibits Her2. Despite this progress not all patients with Her2 positive metastatic breast cancer respond to trastuzumab and patients with metastatic disease who do respond usually develop progressive disease during treatment with trastuzumab. The mechanism of such resistance is unknown. We propose to investigate the mechanism of trastuzumab resistance in Her2 positive breast cancer. The hypothesis to be examined in the basic science section of this study is that IRS-1 and IRS-2 are modifiers of HER2 signaling and that these adapter proteins could be predictive indicators of treatment response to Herceptin in patients that are candidates for this targeted therapy. The connection between IRS-1 and IRS-2 expression and Herceptin response and clinical outcome in HER2 positive human breast tumors will be evaluated to determine if IRS expression correlates with resistance to Herceptin therapy and with the aggressive behavior of these tumors. This study will establish if the IRS proteins influence HER2 function in tumors and if they are predictive markers for evaluating treatment options for HER2 positive patients.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00657345
The ClinicalTrials.gov registry entry for NCT00657345 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Massachusetts, Worcester, which has 240 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00657345 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00657345 about?
NCT00657345 is a clinical study titled "IRS Proteins and Trastuzumab Resistance". Significant progress has been made in the treatment of women with Her2 positive breast cancer who are treated with trastuzumab, a humanized monoclonal antibody that inhibits Her2. Despite this progress not all patients with Her2 positive metastatic breast cancer respond to trastuzumab and patients w...
What is the current status of trial NCT00657345?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2008-03. Estimated completion is 2013-02.
Who is sponsoring clinical trial NCT00657345?
This trial is sponsored by University of Massachusetts, Worcester, which has 240 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.